Hypoglycaemia: difference between revisions
Diff·revision 4 → 5·05:54, 22 Sep 2024
Difference between revision 4 and revision 5 of Hypoglycaemia. 4 lines changed; the page grew by 476 bytes.
| Revision 4 — 10:26, 5 Sep 2024 MTC_Marisol (talk) add the interaction with the mechanism that explains it 2,014 bytes +235 | Revision 5 — 05:54, 22 Sep 2024 ListMakerLumi (talk) rm the reassurance sentence; the article should report, not reassure 2,490 bytes +476 | ||
|---|---|---|---|
| 18 | Sulfonylureas act on the trigger, closing the potassium channel pharmacologically regardless of glucose, which is why they cause hypoglycaemia. Injected insulin bypasses the beta cell entirely. | 18 | Sulfonylureas act on the trigger, closing the potassium channel pharmacologically regardless of glucose, which is why they cause hypoglycaemia. Injected insulin bypasses the beta cell entirely. |
| 19 | 19 | ||
| + | 20 | This is a mechanistic argument rather than a guarantee. Reported hypoglycaemia rates on incretin monotherapy are low but not zero, and the residual reflects other contributors — missed meals, alcohol, renal impairment, and concurrent agents.{{r|drucker2018}} | |
| + | 21 | ||
| 20 | == References == | 22 | == References == |
| 21 | {{reflist}} | 23 | {{reflist}} |
| 22 | <ref name="ada2024">American Diabetes Association. "Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> | 24 | <ref name="ada2024">American Diabetes Association. "Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> |
| 23 | <ref name="nauck2016">Nauck MA, Meier JJ. "The incretin effect in healthy individuals and those with type 2 diabetes." ''The Lancet Diabetes & Endocrinology'' 4(6):525–536 (2016). PMID 26876794.</ref> | 25 | <ref name="nauck2016">Nauck MA, Meier JJ. "The incretin effect in healthy individuals and those with type 2 diabetes." ''The Lancet Diabetes & Endocrinology'' 4(6):525–536 (2016). PMID 26876794.</ref> |
| + | 26 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> | |
| 24 | 27 | ||
| 25 | {{DEFAULTSORT:Hypoglycaemia}} | 28 | {{DEFAULTSORT:Hypoglycaemia}} |
| 26 | [[Category:Adverse effects]] | 29 | [[Category:Adverse effects]] |
| 27 | [[Category:Clinical practice]] | 30 | [[Category:Clinical practice]] |
| + | 31 | [[Category:Metabolic biomarkers]] | |
| 28 | 32 |